APP Pharmaceuticals, Inc., formerly traded on the NASDAQ Capital Market
under the symbol APPX, today announced that the NASDAQ Global Market has
accepted for listing the Contingent Value Rights (CVRs) related to the
acquisition of APP by Fresenius Kabi, a business segment of Fresenius
SE. The CVRs will trade under the symbol “APCVZ”
beginning on Thursday, September 11, 2008.
The acquisition of APP was completed earlier today. On July 7, 2008,
Fresenius announced the agreement to acquire Schaumburg, Illinois-based
APP Pharmaceuticals, Inc. Under the terms of the agreement, Fresenius
acquired the outstanding common stock of APP for $23.00 in cash per
share (the “Cash Purchase Price”)
plus a CVR that could deliver up to an additional $980 million, or $6.00
per CVR in cash, if the financial results of APP meet certain targets
(payable in Q2 2011).
About Fresenius SE
Fresenius is a health care group with international operations,
providing products and services for dialysis, hospital and outpatient
medical care. In 2007, group sales were approximately €
11.4 billion. On June 30, 2008 the Fresenius Group had 117,453 employees
worldwide. For more information visit the company’s
website at www.fresenius.com.
About Fresenius Kabi
Fresenius Kabi is the leader in infusion therapy and clinical nutrition
in Europe and in its most important countries of Latin America and Asia
Pacific. Fresenius Kabi’s core product range
includes infusion solutions for fluid substitution, blood volume
expansion and parenteral nutrition, as well as products for enteral
nutrition. Furthermore, the company provides concepts for ambulatory
health care and is focused on managing and providing home therapies.
With its philosophy “Caring for life”
and a comprehensive product portfolio, the company aims at improving the
quality of life of patients all over the world. On June 30, 2008 the
company had 18,323 employees. In 2007, Fresenius Kabi achieved sales of €
2,030 million and an operating profit of €
332 million. Fresenius Kabi AG is a 100% subsidiary of the health care
group Fresenius SE.
About APP Pharmaceuticals, Inc.
APP is a fully-integrated pharmaceutical company that develops,
manufactures and markets injectable pharmaceutical products with a
primary focus on the oncology, anti-infective, anesthetic/analgesic and
critical care markets.
